Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jul 11;318(2):197-198.
doi: 10.1001/jama.2017.7156.

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

Ethan Basch  1 , Allison M Deal  2 , Amylou C Dueck  3 , Howard I Scher  4 , Mark G Kris  4 , Clifford Hudis  5 , Deborah Schrag  6
Affiliations
Comparative Study

Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment

Ethan Basch et al. JAMA. .

Abstract

This study assesses overall survival associated with electronic patient-reported symptom monitoring vs usual care during routine cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported. Dr Scher reports receiving personal fees from Astellas, BIND Pharmaceuticals, Clovis Oncology, Merck, Roche, Asterias Biotherapeutics, WIRB-Copernicus Group, and Sanofi Aventis; nonfinancial support from Ferring Pharmaceuticals, Janssen Research and Development, Medivation, and Takeda Millennium; and grants from Medivation, Janssen, Illumina, and Innocrin Pharma. Dr Kris reports receiving personal fees from Genetech/Roche, AstraZeneca, and ARIAD. No other disclosures were reported.

Figures

Figure.
Figure.. Overall Survival Among Patients With Metastatic Cancer Assigned to Electronic Patient-Reported Symptom Monitoring During Routine Chemotherapy vs Usual Care
Crosses indicate censored observations. Enrollment in the patient-reported symptom monitoring group was enriched for a preplanned subgroup with low baseline computer experience as part of a feasibility substudy with a 2:1 randomization ratio in that subgroup (N = 227) and a 1:1 ratio in the computer-experienced subgroup (N = 539), yielding 441 participants in the patient-reported symptom monitoring group, and 325 in the usual care group. With a minimum follow-up of 5.4 years, median follow-up was 6.9 years (interquartile range, 6.5-7.7) for the electronic patient-reported symptom monitoring group and 7 years (interquartile range, 6.6-8.1) for the usual care group.
See this image and copyright information in PMC

Comment in

References

    1. Reilly CM, Bruner DW, Mitchell SA, et al. . A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer. 2013;21(6):1525-1550. - PMC - PubMed
    1. Pakhomov SV, Jacobsen SJ, Chute CG, Roger VL. Agreement between patient-reported symptoms and their documentation in the medical record. Am J Manag Care. 2008;14(8):530-539. - PMC - PubMed
    1. Kotronoulas G, Kearney N, Maguire R, et al. . What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? a systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480-1501. - PubMed
    1. Basch E, Deal AM, Kris MG, et al. . Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557-565. - PMC - PubMed